DISCUSSION The absence of a tempera

DISCUSSION
The absence of a temperature reaction agreeswithresultsofpreviousstudies9,18. The prepatent periods reported here (1to5days)aresimilartoresultsreported previously: Potgieter18 found prepatent periods of 3 to 28 days, while Futter & Belonje9 foundparasitesonbloodsmears within 24 to 48 hours post infection.
The differences in prepatent periods in cats housed at OVARU and PS-OVI, respectively,maybeattributabletodifferences in inocula and/or recipients. Although the 2 donor cats had been infectedwiththesameB.felisisolateandthe parasitaemiasofinoculaweresimilar,one cannot assume that they were identical. The recipients housed at PS-OVI had been held in familiar surroundings for a few months, while those at OVARU had been in residence for 14 days only, and may still have been stressed and thus more susceptible to infection. In all cats, however, parasitaemias increased to levels high enough for drug screening.
The anti-babesial action of primaquine foundinthisstudyconfirmedtheresults reportedbyPotgieter18.Primaquinehada dramatic effect on parasitaemia, particularly in control cats 2 and 3 (Fig. 1). Primaquine failed to sterilise the infections, however: 2 of the cats still yielded parasites on blood smear examination 12 months after conclusion of the trial.
For2daysafterthe1stadministrationof buparvaquone it appeared as if the drug would have similar anti-babesial propertiestoprimaquine.Onthe3rdday,when the 2nd treatment was administered, the parasitaemia in both cats began to rise rapidly, increasing to such a level that they had to be removed from the trial. After treatment with primaquine, the PCV of both cats took c.48 h longer to recover than that of the control cats. Buparvaquone is therefore not regarded as suitable for the treatment of B. felis infection.
Rifampicin appeared to have an antiparasitic effect, preventing the parasitaemia from increasing but not causing it to decrease substantially. The sustained decrease in PCV despite stabilisation of the parasitaemia renders rifampicin unsuitable for treatingB.felisinfections.
Theresponsetotreatmentwithsulphadiazine-trimethoprimwasverysimilarto that recorded for rifampicin. The parasitaemia stabilised or gradually decreased, but this was accompanied by a dramatic drop in PVC
The fluoroquinolone drugs (enrofloxacin,danofloxacin)hadnoeffectonparasitaemia, which increased steadily in all 4 cats.
None of the 5 drugs screened proved superiortoprimaquinefortreatingB.felis infections in domestic cats. Buparvaquone, enrofloxacin and danofloxacin were ineffective in reducing parasitaemias and are contra-indicated for use against B. felis. Rifampicin and sulphadiazine-trimethoprim had some antiparasiticeffectandmaybeusefulasinitial treatment if primaquine is not readily available. The use of rifampicin and sulphadiazine-trimethoprim in combination with other drugs should be investigated.
This report emanates from project 36.5.123 approved by the Research and Animal Use and Care Committees, Faculty of Veterinary Science, University of Pretoria.

Kết quả (Việt) 1:

Parasitaemia và PVC mèo vào phác điều trị khác nhau đã như sau: hình 1 (nhóm I, primaquine), hình 2 (nhóm II, buparvaquone), hình 3 (nhóm III, rifampicin), hình 4 (nhóm IV, sulphadiazine-trimethoprim), hình 5 (GroupV, enrofloxacin) và hình 6 (nhóm VI, danofloxacin).

Kết quả (Việt) 2:

Ký sinh trùng và PCV mèo vào phác đồ điều trị khác nhau như sau: Hình. 1 (nhóm I, primaquine), hình. 2 (nhóm II, buparvaquone), hình. 3 (nhóm III, rifampicin), hình. 4 (nhóm IV, sulphadiazine-trimethoprim), hình. 5 (GroupV, enrofloxacin) và hình. 6 (Nhóm VI, danofloxacin).